Alnylam Pharmaceuticals

Alnylam uses RNA interference — a Nobel Prize-winning mechanism that silences disease-causing genes before they produce harmful proteins. This is fundamentally different from antisense oligonucleotides (which block mRNA) or mRNA therapies (which encode proteins). The company's key innovation is a GalNAc sugar-conjugate delivery system that targets siRNA molecules directly to the liver with high specificity, enabling subcutaneous dosing rather than intravenous infusions.

Alnylam has five approved products: ONPATTRO (patisiran), GIVLAARI (givosiran), OXLUMO (lumasiran), AMVUTTRA (vutrisiran), and Leqvio (inclisiran, commercialized by Novartis under a licensing deal). ONPATTRO and AMVUTTRA both treat transthyretin-mediated amyloidosis, GIVLAARI treats acute hepatic porphyria, OXLUMO treats primary hyperoxaluria type 1, and Leqvio lowers LDL cholesterol.

Yvonne Greenstreet has been CEO since 2021, succeeding founding CEO John Maraganore, who led the company for 19 years from discovery to commercial phase. Maraganore now runs an investment vehicle focused on the next generation of biotech founders. Pushkal Garg is the Chief Medical Officer, and Tolga Tanguler serves as Chief Commercial Officer. The executive team blends deeply tenured Alnylam veterans with experienced pharmaceutical commercial operators recruited as the company scaled.

Alnylam typically retains full US and European commercial rights to its core rare-disease products while using partnerships to access geography or therapeutic areas outside its franchise. The Regeneron collaboration focuses on CNS and ocular targets including the Alzheimer's program ALN-APP. The Roche deal covers zilebesiran for hypertension. The Sanofi alliance originally covered global rights to patisiran but was restructured in 2018, giving Alnylam full US/EU rights in exchange for tiered royalties to Sanofi.

The HELIOS-B Phase 3 study, reported in November 2023, demonstrated that vutrisiran reduced both all-cause mortality and cardiovascular events in patients with ATTR amyloidosis with cardiomyopathy. This expands the addressable population from a roughly 50,000-patient polyneuropathy market to a 300,000-plus-patient cardiomyopathy market (public record). A label expansion to include cardiomyopathy would likely add several billion dollars in peak annual revenue for the franchise.

Alnylam is not yet consistently GAAP-profitable, though its product revenues exceed $1.2B annually. The company invests roughly $1B per year in R&D to advance its pipeline toward prevalent-disease indications. Its financial model layers product revenue from rare-disease franchises with milestone payments and royalties from partnered programs, creating a blended revenue stream that partially funds internal development.

Alnylam occupies a unique niche as the only independent, fully integrated leader in RNAi therapeutics. Other companies in the nucleic-acid space include Ionis (antisense, partnered broadly with Biogen and Novartis) and Moderna (mRNA, vaccine-centric). Alnylam's vertical integration — owning the chemical platform, manufacturing, clinical development, and commercial infrastructure — makes it a standalone entity distinct from platform companies that rely entirely on partners for commercial execution.